These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Early prognosis of hormone refractoriness development in inflammatory intestinal diseases]. Baryshnikov EN Eksp Klin Gastroenterol; 2007; (5):138-44. PubMed ID: 18389610 [No Abstract] [Full Text] [Related]
25. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease. van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146 [TBL] [Abstract][Full Text] [Related]
27. Spontaneous formation of immunogenic conjugates by 5-aminosalicylic acid--a biotransformation product of salicylazosulfapyridine. Cîrstea M; Suhaciu G; Cîrje M Physiologie; 1983; 20(3):161-7. PubMed ID: 6139832 [TBL] [Abstract][Full Text] [Related]
28. Salazopyrin metabolism in ulcerative colitis. Das KM; Eastwood MA; Macmanus JP; Sircus W Gut; 1972 Oct; 13(10):840. PubMed ID: 4404480 [No Abstract] [Full Text] [Related]
29. [The role of cytokines in the pathogenesis of inflammatory intestinal diseases]. Hommes DW; van Dullemen H; Radema SA; Tytgat GN; van Deventer SJ Ned Tijdschr Geneeskd; 1994 Dec; 138(49):2427-32. PubMed ID: 7997297 [No Abstract] [Full Text] [Related]
30. A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals. Del Soldato P; Campieri M; Brignola C; Bazzocchi G; Gionchetti P; Lanfranchi GA; Tamba M Gastroenterology; 1985 Nov; 89(5):1215-6. PubMed ID: 2864302 [No Abstract] [Full Text] [Related]
31. [Treatment of ulcerative colitis with salicylazosulfapyridine]. ROTA L Riforma Med; 1953 May; 67(18):501-2. PubMed ID: 13089374 [No Abstract] [Full Text] [Related]
32. Response of ulcerative colitis to therapy with salicylazosulfapyridine. MORRISON LM J Am Med Assoc; 1953 Jan; 151(5):366-8. PubMed ID: 13010999 [No Abstract] [Full Text] [Related]
33. Results of treatment of ulcerative colitis with salicylazosulfapyridine. MORRISON LM Gastroenterology; 1952 May; 21(1):133-8. PubMed ID: 14926821 [No Abstract] [Full Text] [Related]
34. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
35. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H; Munakata A; Yoshida Y J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870 [TBL] [Abstract][Full Text] [Related]
36. [40 years of salazosulfapyridine. Is end in sight?]. van Hees PA; van Tongeren JH Ned Tijdschr Geneeskd; 1982 Oct; 126(44):2014-8. PubMed ID: 6129576 [No Abstract] [Full Text] [Related]
37. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. MOERTEL CG; BARGEN JA Ann Intern Med; 1959 Nov; 51():879-89. PubMed ID: 14423204 [No Abstract] [Full Text] [Related]
38. [Possible mechanism of action of Azulfidine/Salazopyrin]. Campbell DE Z Gastroenterol Verh; 1981 Jun; 19():15-20. PubMed ID: 6168126 [No Abstract] [Full Text] [Related]